153 related articles for article (PubMed ID: 23142468)
21. Enantioselective CE analysis of hepatic ketamine metabolism in different species in vitro.
Schmitz A; Thormann W; Moessner L; Theurillat R; Helmja K; Mevissen M
Electrophoresis; 2010 May; 31(9):1506-16. PubMed ID: 20358543
[TBL] [Abstract][Full Text] [Related]
22. Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase.
Wang PF; Neiner A; Kharasch ED
Anesthesiology; 2018 Oct; 129(4):756-768. PubMed ID: 30085944
[TBL] [Abstract][Full Text] [Related]
23. Role of human CYP2B6 in S-mephobarbital N-demethylation.
Kobayashi K; Abe S; Nakajima M; Shimada N; Tani M; Chiba K; Yamamoto T
Drug Metab Dispos; 1999 Dec; 27(12):1429-33. PubMed ID: 10570024
[TBL] [Abstract][Full Text] [Related]
24. Functional characterization of cytochrome P450 2B6 allelic variants.
Jinno H; Tanaka-Kagawa T; Ohno A; Makino Y; Matsushima E; Hanioka N; Ando M
Drug Metab Dispos; 2003 Apr; 31(4):398-403. PubMed ID: 12642465
[TBL] [Abstract][Full Text] [Related]
25. Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.
Talakad JC; Kumar S; Halpert JR
Drug Metab Dispos; 2009 Mar; 37(3):644-50. PubMed ID: 19074527
[TBL] [Abstract][Full Text] [Related]
26. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation.
Bumpus NN; Sridar C; Kent UM; Hollenberg PF
Drug Metab Dispos; 2005 Jun; 33(6):795-802. PubMed ID: 15769884
[TBL] [Abstract][Full Text] [Related]
27. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
28. Haplotype structure and allele frequencies of CYP2B6 in a Korean population.
Cho JY; Lim HS; Chung JY; Yu KS; Kim JR; Shin SG; Jang IJ
Drug Metab Dispos; 2004 Dec; 32(12):1341-4. PubMed ID: 15383491
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer.
Kumagai J; Fujimura T; Takahashi S; Urano T; Ogushi T; Horie-Inoue K; Ouchi Y; Kitamura T; Muramatsu M; Blumberg B; Inoue S
Prostate; 2007 Jul; 67(10):1029-37. PubMed ID: 17455229
[TBL] [Abstract][Full Text] [Related]
30. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
31. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility.
Yuan ZH; Liu Q; Zhang Y; Liu HX; Zhao J; Zhu P
Ann Hematol; 2011 Mar; 90(3):293-9. PubMed ID: 20878158
[TBL] [Abstract][Full Text] [Related]
32. Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether.
Honda M; Muroi Y; Tamaki Y; Saigusa D; Suzuki N; Tomioka Y; Matsubara Y; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2011 Oct; 39(10):1860-5. PubMed ID: 21746968
[TBL] [Abstract][Full Text] [Related]
33. Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy.
Dickmann LJ; Isoherranen N
Drug Metab Dispos; 2013 Feb; 41(2):270-4. PubMed ID: 22815312
[TBL] [Abstract][Full Text] [Related]
34. Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions.
Mayumi K; Hanioka N; Masuda K; Koeda A; Naito S; Miyata A; Narimatsu S
Biochem Pharmacol; 2013 Apr; 85(8):1182-94. PubMed ID: 23395694
[TBL] [Abstract][Full Text] [Related]
35. A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein.
Tychopoulos M; Corcos L; Genne P; Beaune P; de Waziers I
Cancer Gene Ther; 2005 May; 12(5):497-508. PubMed ID: 15746946
[TBL] [Abstract][Full Text] [Related]
36. Oxidative metabolism of BDE-99 by human liver microsomes: predominant role of CYP2B6.
Erratico CA; Szeitz A; Bandiera SM
Toxicol Sci; 2012 Oct; 129(2):280-92. PubMed ID: 22738989
[TBL] [Abstract][Full Text] [Related]
37. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer.
Wang SC; Ho IK; Tsou HH; Tian JN; Hsiao CF; Chen CH; Tan HK; Lin L; Wu CS; Su LW; Huang CL; Yang YH; Liu ML; Lin KM; Chen CY; Liu SC; Wu HY; Chan HW; Tsai MH; Lin PS; Liu YL
J Clin Psychopharmacol; 2011 Aug; 31(4):463-9. PubMed ID: 21694616
[TBL] [Abstract][Full Text] [Related]
38. Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance.
Rao LK; Flaker AM; Friedel CC; Kharasch ED
Anesthesiology; 2016 Dec; 125(6):1103-1112. PubMed ID: 27763887
[TBL] [Abstract][Full Text] [Related]
39. Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools.
Radloff R; Gras A; Zanger UM; Masquelier C; Arumugam K; Karasi JC; Arendt V; Seguin-Devaux C; Klein K
Hum Mutat; 2013 May; 34(5):725-34. PubMed ID: 23418033
[TBL] [Abstract][Full Text] [Related]
40. CE provides evidence of the stereoselective hydroxylation of norketamine in equines.
Schmitz A; Theurillat R; Lassahn PG; Mevissen M; Thormann W
Electrophoresis; 2009 Aug; 30(16):2912-21. PubMed ID: 19653235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
